Company / SG&A Expense
Kura Oncology, Inc. SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$120.0M
FY2025
5-year range
$46.5M / $120.0M
FY2021-FY2025
Trend
+55.6%
vs FY2024
Sector context
#103 of 213
Health Care
What the data says
At $120M, Kura Oncology, Inc.'s sg&a expense ranks #111 of 213 in the Health Care sector. SG&A Expense has increased for 8 consecutive years, from $10M in FY2017 to $120M in FY2025.
Based on SEC 10-K filings.
$120M in FY2025 with a 5-year CAGR of +30.7%.
Increased from $51M to $120M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +36.6%
- 5-Year CAGR
- +30.7%
- 10-Year CAGR
- -
Sector benchmark
#111 of 213 in Health CareTop 52% of 213This company $120.0M Sector average $722.3M
▼
-83.4% below sector average
Key checks
Key Insights
- Kura Oncology, Inc.'s sg&a expense has grown for 8 consecutive years.
- 5-year CAGR of +30.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 55.6% year-over-year.
- Ranks #103 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $120.0M | +55.6% |
| FY2024 | $77.1M | +52.5% |
| FY2023 | $50.6M | +7.5% |
| FY2022 | $47.1M | +1.1% |
| FY2021 | $46.5M | +47.7% |
| FY2020 | $31.5M | +60.3% |
| FY2019 | $19.7M | +22.1% |
| FY2018 | $16.1M | +66.8% |
| FY2017 | $9.7M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026